FedEx, Sarepta Therapeutics and more

FedEx, Sarepta Therapeutics and more

Engineers move a 350-volt battery to be installed in a Fedex Corp. van. Express General Motors Co. (GM) at the VIA Motors Inc. plant in Orem, Utah, U.S., on Monday February 17, 2014.

George Frey | Bloomberg | Getty Images

Here are the stocks making headlines after the bell.

FedEx – Shares of the shipping company rose more than 3% after FedEx issued an upbeat outlook for its full year, forecasting an increase in adjusted earnings. FedEx reported mixed results for its recently completed fiscal fourth quarter, with $6.87 in adjusted earnings per share on $24.39 billion in revenue. Analysts polled by Refinitiv had expected $6.86 in earnings per share on $24.56 billion in revenue.

Sarepta Therapeutics – Biopharma stock fell more than 5% in extended trading after the FDA clinically suspended Sarepta’s treatment for Duchenne muscular dystrophy. Sarepta said there was a “serious adverse event” in one of the treatment studies.

Smith & Wesson brands – Shares in the firearms maker fell about 2% after Smith & Wesson’s fiscal fourth quarter report showed a year-over-year drop in revenue and sales. Gross margin. The company, which has a market capitalization of about $650 million, increased its split quarterly to 10 cents a share from 8 cents.

(Visited 1 times, 1 visits today)

Be the first to comment

Leave a comment

Your email address will not be published.